Arbutus Biopharma (NASDAQ:ABUS) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other equities analysts have also recently commented on ABUS. Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a report on Monday, August 7th. Wedbush reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Arbutus Biopharma in a report on Wednesday, September 20th. ValuEngine raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. JMP Securities reaffirmed an “outperform” rating and issued a $13.00 target price (up from $12.00) on shares of Arbutus Biopharma in a report on Wednesday, October 4th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $5.00 target price (up from $4.00) on shares of Arbutus Biopharma in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $13.00.

Arbutus Biopharma (NASDAQ ABUS) traded down $0.10 during mid-day trading on Friday, reaching $5.55. 193,691 shares of the company’s stock were exchanged, compared to its average volume of 209,921. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03. Arbutus Biopharma has a 12 month low of $2.35 and a 12 month high of $8.25.

In other news, insider Michael J. Sofia sold 10,000 shares of Arbutus Biopharma stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total value of $80,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 10.00% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. RTW Investments LP increased its holdings in shares of Arbutus Biopharma by 1.1% in the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after acquiring an additional 56,457 shares during the period. Bank of Montreal Can grew its position in Arbutus Biopharma by 1.9% in the 2nd quarter. Bank of Montreal Can now owns 874,254 shares of the biopharmaceutical company’s stock valued at $3,147,000 after buying an additional 16,535 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Arbutus Biopharma in the 3rd quarter valued at $1,393,000. Victory Capital Management Inc. purchased a new position in Arbutus Biopharma in the 2nd quarter valued at $478,000. Finally, Renaissance Technologies LLC grew its position in Arbutus Biopharma by 785.1% in the 1st quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 110,499 shares during the last quarter. 60.00% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “BidaskClub Downgrades Arbutus Biopharma (ABUS) to Sell” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/02/bidaskclub-downgrades-arbutus-biopharma-abus-to-sell.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.